» Articles » PMID: 23851720

Practices and Impact of Primary Outcome Adjustment in Randomized Controlled Trials: Meta-epidemiologic Study

Overview
Journal BMJ
Specialty General Medicine
Date 2013 Jul 16
PMID 23851720
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess adjustment practices for primary outcomes of randomized controlled trials and their impact on the results.

Design: Meta-epidemiologic study.

Data Sources: 25 biomedical journals with the highest impact factor according to Journal Citation Reports 2009.

Study Selection: Randomized controlled trials published in print in 2009 that reported primary outcomes. The search yielded 684 eligible papers of randomized controlled trials, of which 200 were randomly selected.

Data Extraction: Two researchers independently extracted data on study population, intervention, primary outcome, and the adjustment plan for primary outcomes. They also recorded the magnitude and statistical significance of the intervention effect with and without adjustments, and estimated whether adjustment made a difference in the level of nominal significance. They also compared the analysis plan for model adjustment in the published trial versus the trial protocol with information on the protocol collected from registries, design papers, and communication with all corresponding authors.

Results: 54% of the trials used stratified randomization, 96% presented baseline characteristics in the compared arms, and 46% also evaluated differences in baseline factors with statistical testing. Half of the trials performed adjusted analyses for the main outcome, as the sole analysis (29%) or along with unadjusted analyses (21%). Adjustment for stratification variables and for baseline variables was performed in 39% (42/108) and 42% (84/199) of the trials, respectively. Among 40 comparisons with both adjusted and unadjusted analyses, 43% had statistically significant effects, 40% had non-significant effects, and 18% had significant effects with only one of the two analyses, but not with the other. Information on analysis plan regarding model adjustment was available in 6% (9/162) of trial registry entries, 78% (21/27) of design papers, and 74% (40/54) of protocols obtained from authors. The analysis plan disagreed between the published trial and the registry, protocol, or design paper in 47% (28/60) of the studies.

Conclusions: There is large diversity on whether and how analyses of primary outcomes are adjusted in randomized controlled trials and these choices can sometimes change the nominal significance of the results. Registered protocols should explicitly specify adjustments plans for main outcomes and analysis should follow these plans.

Citing Articles

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper.

Armeni K, Chambers L, Peachey A, Berk J, Langdon K, Peterson L BMJ Open. 2024; 14(11):e085888.

PMID: 39521460 PMC: 11551980. DOI: 10.1136/bmjopen-2024-085888.


Predictive Tool Use and Willingness for Surgery in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.

Zhou Y, Patten L, Spelman T, Bunzli S, Choong P, Dowsey M JAMA Netw Open. 2024; 7(3):e240890.

PMID: 38457182 PMC: 10924247. DOI: 10.1001/jamanetworkopen.2024.0890.


Estimating the prevalence of discrepancies between study registrations and publications: a systematic review and meta-analyses.

BMJ Open. 2023; 13(10):e076264.

PMID: 37793922 PMC: 10551944. DOI: 10.1136/bmjopen-2023-076264.


Are we leaving money on the table in infertility RCTs? Trialists should statistically adjust for prespecified, prognostic covariates to increase power.

Wilkinson J, Showell M, Taxiarchi V, Lensen S Hum Reprod. 2022; 37(5):895-901.

PMID: 35199145 PMC: 9071217. DOI: 10.1093/humrep/deac030.


Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol.

Matsuoka H, Clark K, Fazekas B, Oyamada S, Brown L, Ishiki H BMJ Open. 2022; 12(2):e050182.

PMID: 35131817 PMC: 8823224. DOI: 10.1136/bmjopen-2021-050182.


References
1.
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F . Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009; 27(12):1999-2006. DOI: 10.1200/JCO.2008.19.6618. View

2.
Diggle P, Zeger S . Embracing the concept of reproducible research. Biostatistics. 2010; 11(3):375. DOI: 10.1093/biostatistics/kxq029. View

3.
Vandemheen K, OConnor A, Bell S, Freitag A, Bye P, Jeanneret A . Randomized trial of a decision aid for patients with cystic fibrosis considering lung transplantation. Am J Respir Crit Care Med. 2009; 180(8):761-8. DOI: 10.1164/rccm.200903-0421OC. View

4.
Kesecioglu J, Beale R, Stewart T, Findlay G, Rouby J, Holzapfel L . Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009; 180(10):989-94. DOI: 10.1164/rccm.200812-1955OC. View

5.
Chan A, Krleza-Jeric K, Schmid I, Altman D . Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004; 171(7):735-40. PMC: 517858. DOI: 10.1503/cmaj.1041086. View